PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)
May 1, 2008, 00:00
10.1016/S1098-3015(10)70960-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)70960-8/fulltext
Title :
PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70960-8&doi=10.1016/S1098-3015(10)70960-8
First page :
Section Title :
Open access? :
No
Section Order :
724